The combined efficacy of multimodal non-surgical treatment on pain and sensitization in patients with knee osteoarthritis not eligible for a total knee arthroplasty – An ancillary analysis from a randomized controlled trial  by Skou, S.T. et al.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A34Methods: Primary human chondrocytes from human donors (mean ±
SD 76,75 ± 3,30 years, n¼3) were transfected with siRNA for Atg5 (100
nM, 72 hours), an important autophagy marker, and silencer negative
control siRNA (100 nM) used as control to block the autophagy pathway.
To identify the key proteins responding to defective autophagy, we
performed a quantitative proteomics analysis of autophagy-deﬁcient
human chondrocytes using labeling iTRAQ (isobaric tags for relative and
absolute quantitation) coupled with on-line 2D LC/MS/MS. Protein
identiﬁcation and quantiﬁcation were performed using Protein Pilot
Software v 4.0 (ABSciex). Each MS/MS spectrum was searched in the
Uniprot/Swissprot database for Homo sapiens. The String database was
employed to ﬁnd putative protein-protein interactions. To validate the
candidate targets identiﬁed by the proteomic screening, inmortalized
human chondrocytes (Tc28a2), Human cartilage from healthy, aged and
osteoarthritis human patients and mouse knee joints from young and
old mice were employed to perform Western Blot (WB), Inmuno-
ﬂuorescence (IF) and Inmunohistochemistry (IHC) analysis, respec-
tively. The candidate targets were: Atg5 and LC3 for constitutive
autophagy, p62, as a defective autophagy marker, Lamin A/C as an aging
marker and Filamin A, as a cytoskeleton marker.
Results: From the total of 1216 proteins found, 21 were signiﬁcantly
altered (p < 0.05) in at least two donors from a total number of three.
However, only prelamin A/C, a nuclear protein implicated in premature
cell senescence, was signiﬁcantly upregulated in all the donors (p <
0.05). Furthermore, proteins involved in the cytoskeleton organization,
collagen catabolism, oxidative stress, and aging were identiﬁed in
deﬁcient autophagy chondrocytes. Interestingly, the String Database
Software indicates a direct interaction between Filamin A, a cytoske-
leton protein (p < 0.05) and Prelamin A/C, an aging marker, that were
downregulated and upregulated ,respectively when autophagy is
blocked. To conﬁrm this association, TC28a2 human chondrocytes were
transfected with siAtg5 and silencer negative control siRNA. Then, the
expression of autophagy proteins, such as Atg5 and LC3, the levels of
p62, Lamin A/C and Filamin A was evaluated. The results indicated a
reduction in autophagy expression, accompanied with an increase in
p62 and Lamin A/C and a reduction in Filamin A expression. Impor-
tantly, in human cartilage from both aged and OA patients, autophagy
markers were signiﬁcantly downregulated and Lamin A/C expression
was upregulated, compared to healthy cartilage. To stablish the validity
of these results, articular cartilage from a spontaneous aging mice
model was studied. Histology analysis of mouse knee joints from young
mice (4 months old mice) and old mice (28 months old) revealed a
reduction in Atg5 and LC3 expression, as well as an increase in Lamin A/
C expression, suggesting that autophagy loss-of-function is directly
correlated with premature senescence in articular cartilage.
Conclusions: Proteomics analysis of joint cells and tissue has revealed
features of premature senescence when autophagy is disrupted in
chondrocytes and cartilage. Lamin, nuclear protein contributing to
structural integrity to the nucleus and matrix was identiﬁed as candi-
date targets for regulating cartilage function in situations of defective
autophagy, including aging and OA. These results support the hypoth-
esis that autophagy is decreased with aging, affect nuclear and matrix
structural integrity, and represents a key mechanism in the develop-
ment of cartilage degradation. Therefore, targeting lamin is a promising
strategy to ﬁnd novel therapeutics for cartilage aging and OA.
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EVALUATION OF THE BENEFIT OF CORTICOSTEROID INJECTION
PRIOR TO EXERCISE THERAPY IN PATIENTS WITH KNEE
OSTEOARTHRITIS: A RANDOMIZED TRIAL
M. Henriksen, R. Christensen, L. Klokker, C. Bartholdy, K. Ellegaard,
M. Boesen, R. Riis, E. Bartels, H. Bliddal. The Parker Inst., Copenhagen,
Denmark
Purpose: Combined non-pharmacological and pharmacological treat-
ment is recommended as optimal management of knee osteoarthritis
(OA). However, the two treatment approaches have mostly been
investigated separately. We aimed to assess the efﬁcacy of combined
intra-articular corticosteroid injection and exercise compared to pla-
cebo injection and exercise in patients with knee OA.
Methods: This randomized, double blind, placebo-controlled trial
running over 26 weeks was designed as a superiority study comparing
the efﬁcacy of a single intra-articular corticosteroid injection (1 mL of
40 mg/mL methylprednisolone dissolved in 4 mL 10 mg/mL Lidocaine)
plus exercise, with a single placebo injection (1 mL isotonic salinemixed with 4 mL 10 mg/mL Lidocaine) plus exercise. Participants with
clinical and radiographic knee OA were randomly allocated (1:1) to
either corticosteroid (Steroid Group) or saline (Placebo Group) injec-
tion. Two weeks after injection, all participants started a 12 week
supervised exercise program with 3 weekly sessions. Outcomes were
assessed at baseline, week 2 (exercise start), week 14 (end of exercise),
and week 26 (follow-up). The primary outcomewas themean change in
KOOS pain subscale at week 14. Analyses were done on the intention-
to-treat (ITT) population (all randomized participants). Missing data
were replaced using multiple imputation. A repeated measures mixed
model was used to analyze the primary outcome; week, treatment, and
week x treatment were included as ﬁxed effects, adjusting for the
baseline value.
Results: A total of 263 patients were screened and 100 patients were
randomized to receive either Steroid (n¼50) or Placebo (n¼50). Of
these, 93 completed the week 14 assessment and 89 completed the 26
weeks trial. There were no group differences in the proportions com-
pleting. Mean age was 63.4 (SD 9.3) years, 61% were women. The mean
exercise attendance ratewas 79% (SD 15); no group difference observed.
The mean (SD) KOOS pain score at randomization was 53.3 (11.4) and
55.2 (16.0) in the Steroid and Placebo groups, respectively. The mean
(SE) change in pain at week 14was 13.6 (1.8) and 14.8 (1.8) in the Steroid
and Placebo Groups, respectively, corresponding to amean difference of
1.2 units (95% CI -3.8 to 6.2; P¼0.64). These results were robust
according to all sensitivity analyses - incl. using baseline observation
carried-forward imputation and no imputation. There were no group
differences at week 2, 14, and 26 in any of the 5 KOOS subscales and the
95% conﬁdence intervals of the group differences did not exceed the
suggested minimal clinical important difference of 8-10 KOOS points.
Conclusions: These results show comparable efﬁcacy of intra-articular
corticosteroid and placebo when combined with exercise for pain relief
in knee OA.
Trial registration. EU clinical trials register (EudraCT): 2012-002607-18
and clinicaltrials.gov NCT01945749
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THE COMBINED EFFICACY OF MULTIMODAL NON-SURGICAL
TREATMENT ON PAIN AND SENSITIZATION IN PATIENTS WITH
KNEE OSTEOARTHRITIS NOT ELIGIBLE FOR A TOTAL KNEE
ARTHROPLASTY e AN ANCILLARY ANALYSIS FROM A RANDOMIZED
CONTROLLED TRIAL
S.T. Skou y,z, E. Roos z, O. Simonsen y, M.B. Laursen y, M.S. Rathleff x,
L. Arendt-Nielsen x, S. Rasmussen y. yAalborg Univ. Hosp., Aalborg,
Denmark; zUniv. of Southern Denmark, Odense, Denmark; xAalborg
Univ., Aalborg, Denmark
Purpose: To report the efﬁcacy of a 12-week treatment program con-
sisting of neuromuscular exercise, education, diet, insoles and pain
medication (the MEDIC-treatment) compared to two leaﬂets with
information and treatment advice (usual care) in reducing pain-related
measures and sensitization in patients with knee osteoarthritis (OA) not
eligible for total knee arthroplasty (TKA).
Methods: This was a pre-deﬁned ancillary analysis of the 12-week
results from a randomized controlled trial with 100 patients random-
ized to MEDIC-treatment or usual care (Trial registration: clinicaltrials.
gov NCT01535001). The primary outcomewas peak pain intensity in the
previous 24h (VAS 0-100). Secondary outcomes included peripheral
and central sensitization assessed at the knee, the lower leg and fore-
arm (pressure pain thresholds from handheld algometry), pain inten-
sity after 30 min of walking (VAS 0-100), pain location and pattern
(Knee Pain Map), spreading of pain (a region-divided body chart) and
the usage of pain medication (pain medication during the last week due
to knee yes/no).
Results: 654 patients seen by an orthopaedic surgeon in secondary
care were assessed for eligibility, 553 were excluded and one was
not willing to undergo randomization (Primary reasons for exclu-
sion: being eligible for TKA (n¼192), not radiographic OA (Kellgren-
Lawrence score<1; n¼87), and inability to comply with study pro-
tocol (n¼159)). 100 patients were randomized with 43/50 (86%) in
the MEDIC group and 46/50 (92%) in the usual care group com-
pleting both baseline and the 12-week follow-up (see table 1 for
baseline characteristics).
The MEDIC group had a mean improvement (95% CI) in peak pain
intensity from baseline to 12 weeks that was 15.4 (2.6 to 28.2) larger
(Figure 1; P ¼ 0.019) than the usual care group. Furthermore, the
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A35improvements were larger in theMEDIC group in pain intensity after 30
min of walking and in the number of body sites with pain (P < 0.05).
There was no difference in pain pattern, usage of pain medication or in
the change in sensitization from baseline to 3 months between groups
(P > 0.05), but sensitization improved in both groups P < 0.05).
Conclusions: A multimodal non-surgical treatment program is more
efﬁcacious in reducing self-reported pain-related measures, while it is
not superior to usual care in reducing pain sensitization. This suggests
that other mechanisms than pain sensitization contributed to the per-
ception of pain.Table 1
Baseline characteristics
Baseline characteristics MEDIC (n¼50) Usual care (n¼50)
Women, n (%) 26 (52) 25 (50)
Age (years), mean (SD) 64.8 (8.7) 67.1 (9.1)
Body Mass Index, mean (SD) 30.6 (5.6) 29.4 (5.2)
Radiographic knee OA severity
(Kellgren-Lawrence), n (%)
Grade 1 7 (14) 11 (22)
Grade 2 13 (26) 15 (30)
Grade 3 13 (26) 10 (20)
Grade 4 17 (34) 14 (28)
Peak pain intensity in the previous
24h (VAS 0-100), mean (SD)
60 (23) 56 (25)18
MRI STRUCTURAL PARAMETERS PREDICT SHORT TERM RESPONSE
TO INTRA-ARTICULAR STEROID THERAPY IN KNEE OA
N. Maricar y, M.J. Parkes y, D.T. Felson z, T.F. Cootes y, A.D. Gait y,
E.J. Marjanovic y, D. Bailey x, C.E. Hutchinson x, T.W. O'Neill y. y The Univ.
of Manchester, Manchester, United Kingdom; zBoston Univ., Boston, MA,
United States; x The Univ. of Warwick, Coventry, United Kingdom
Purpose: Osteoarthritis (OA) is a disease of the whole joint. Intra-
articular steroid injection (IASI) is widely used in the management of
knee OA; however, it remains unclear whether structural factors iden-
tiﬁed by magnetic resonance imaging (MRI) may inﬂuence outcome of
therapy. The aim of this analysis was to determine if individual sub-
scores of WORMS assessed prior to IASI of the knee including scores for
cartilage, bone attrition, bone marrow lesions (BMLs), synovitis,
osteophytes, bone cyst, menisci and ligaments, inﬂuence short-term
response to treatment.
Methods: Men and women aged 40 years and older with painful knee
OA who met the American College of Rheumatology criteria for the
disease, were recruited for participation in an open-label clinical trial of
IASI. Subjects who took part in the study had signiﬁcant knee pain
(moderate to severe pain on at least 2 days in the last 2 weeks and/or
Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale >
7) and knee OA; on radiographs at least a Kellgren-Lawrence grade 2 or
more. At baseline they completed questionnaires about their symptomsincluding the KOOS (0-100) with lower scores indicating greater pain
and also a VAS (0-10cm) for pain during a nominated activity (VASNA)
with higher scores indicating greater pain. They subsequently had a
gadolinium (Gd)-enhanced MRI scan using 3-T scanner immediately
prior to having an IASI (depomedrone 80mg) with follow-up visit
usually within a 2-week period. Semi-quantitative grading of the MRI
images using the WORMS protocol was performed for cartilage, bone
attrition, BMLs, synovitis, osteophytes, bone cysts, menisci and liga-
ments within the knee by an experiencedMSK radiologist. For cartilage,
bone attrition, BMLs, osteophytes and bone cyst we focused our anal-
yses on the maximal WORMS score in any region of the knee. Using
linear regression we looked whether these WORMS scores at baseline
were associated with the change in KOOS pain and VASNAbetween
baseline and the follow-up visit, with the results expressed as b
(unstandardised) coefﬁcients and 95% conﬁdence intervals (CI).
Results: 112 participants recruited at baseline had MRI images eval-
uated. Their mean agewas 61.8 years (SD¼10.2 years) and 57 (51%) were
female. The median time between baseline and the follow-up visit was
8 days (IQR 7 to 13 days). During this time there was a signiﬁcant
increase in KOOS (23.0 points; 95% CI 19.0, 27.0) and a reduction in
VASNA (-3.1cm; 95% CI -3.7, -2.6), both indicating an improvement in
pain following steroid injection. Using linear regression, we found that
higher maximal score for BMLs (b coefﬁcient¼ 0.79; 95%CI 0.19, 1.38),
and menisci damage (b coefﬁcient¼ 0.35; 95% CI 0.03, 0.68) were
associated with a smaller reduction in pain as assessed by VASNA
VASnA. Similar trends were observed when KOOS pain was used as the
outcome(data not shown).
Conclusions: To our knowledge, this is the ﬁrst trial that has looked at
WORMS individual structural sub-scores to predict response to IASI.
Persons with more severe structural disease are less likely to have pain
reduction with steroid injection as assessed by MRI markers of disease
severity.
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SUPERVISED NEUROMUSCULAR EXERCISE PRIOR TO HIP OR KNEE
REPLACEMENT: COST-UTILITY ANALYSIS ALONGSIDE A
RANDOMISED CONTROLLED TRIAL
L. Fernandes y,z, E.M. Roos x, S. Overgaard y, A. Villadsen y,
R. Soegaard k. yOdense Univ. Hosp., Odense C, Denmark; zUniv. of
Southern Denmark, Clinical Inst., Odense, Denmark; xUniv. of Southern
Denmark, Inst. of Sports Sci. and Clinical Biomechanics, FOF, Odense,
Denmark; kAarhus Univ., Dept. of Publ. Hlth., Aarhus, Denmark
Purpose: To analyse cost-utility of supervised neuromuscular exercise
prior to total hip replacement (THR) and total knee replacement (TKR).
Methods: Cost-utility analysis was performed alongside a randomised
controlled trial including 165 patients scheduled for THR or TKR
(Clinical Trials registration no.: NCT01003756). An 8-week preoperative
supervised neuromuscular exercise program was provided twice
weekly in addition to standard THR or TKR regimen compared to
standard THR and TKR regimen alone. The analysis applied the health
care sector perspective and used the intention-to-treat approach. The
intervention cost was based on tariff-based costs for physiotherapy.
Individual resource use and tariff-based costs (2012-EUR) for health
care visits in primary and secondary care were extracted from The
Danish National Health Insurance Service Registry and The Danish
National Health Registry. Utility was expressed as quality adjusted life
years (QALY), based on weighted EQ-5D-3L scores. Missing EQ-5D-3L
data was imputed with the linear trend at point method. Incremental
net monetary beneﬁt was analysed to estimate the probability for the
intervention being cost effective and presented in cost effectiveness
acceptability curve (CEAC). The robustness of the cost-utility result was
tested by changing perspective, applying a per-protocol analysis and
limiting analysis to complete item response. The time horizon was 61
weeks including assessment of clinical outcomes at baseline, post-
intervention, and 6 weeks, 3 months and 12 months post-surgery.
Results: A non-signiﬁcant total cost of V132 (95% CI -3942 to 3679) was
observed between the groups. There was a signiﬁcant QALY gain of 0.06
(95% CI, 0.02 to 0.09) in the intervention group as compared to the
control group. At the conventional threshold of V40.000, the inter-
ventionwas found to be cost effective at 89% probability. The cost-utility
analysis was found to be robust (Figure).
Conclusions: Preoperative supervised neuromuscular exercise was
cost-effective in patients scheduled for THR and TKA surgery at con-
ventional thresholds for willingness to pay.
